BioCentury
ARTICLE | Clinical News

PX-12: Phase II started

January 8, 2007 8:00 AM UTC

BRA began an open-label, U.S. Phase II trial in up to 80 patients with advanced pancreatic cancer who are refractory to gemicitabine-containing regimens. BRA gained rights to PX-12 through its 2006 ac...